Signed, Sealed, Weekend – January 9, 2026

Welcome to Signed, Sealed, Weekend, our weekly newsletter recap.

Check out the news of the week:

· SIX-listed Santhera Pharmaceuticals has signed an exclusive licensing agreement with biopharma company Nxera Pharma for the development, manufacturing and commercialization in Japan, South Korea, Australia and New Zealand of Agamree, a prescription medicine used to treat Duchenne muscular dystrophy. Homburger advised Santhera. The company’s CLO, Oliver P. Kronenberg, led Santhera’s in-house team throughout the matter. Nxera worked with Orrick, Herrington & Sutcliffe LLP, which supported on the licence agreement with a US-based team, and with Swiss side Bär & Karrer, advising on the investment agreement.

· Charles Russell Speechlys expanded its litigation and dispute resolution team in Geneva through the appointment of Luca Beffa as partner and leader of the arbitration practice.

· Walder Wyss Ltd. officialised the promotion of Iliana Djagova to partner in the corporate and M&A team, and Matthias Lötscher to counsel in the banking & finance team, both effective from January 1st 2026.

hashtag#LegalcommunityCH hashtag#news